GoodRx Holdings, Inc. Earnings Per Share Disclosure
Year Ended December 31, | |||||
(in thousands, except per share amounts) | 2025 | 2024 | 2023 | ||
Numerator: | |||||
Net income (loss) | $30,439 | $16,390 | $(8,868) | ||
Denominator: | |||||
Weighted average shares - basic | 356,327 | 385,737 | 410,315 | ||
Dilutive impact of stock options and restricted stock units | 646 | 6,435 | — | ||
Weighted average shares - diluted | 356,973 | 392,172 | 410,315 | ||
Earnings (loss) per share: | |||||
Basic | $0.09 | $0.04 | $(0.02) | ||
Diluted | $0.09 | $0.04 | $(0.02) | ||
Year Ended December 31, | |||||
(in thousands) | 2025 | 2024 | 2023 | ||
Stock options and restricted stock units | 47,208 | 20,682 | 46,606 | ||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.